Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Bruce StroberA MenterC LeonardiK GordonJ LambertLluis PuigH PhotowalaM LongcoreT ZhanP FoleyPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Risankizumab demonstrated consistent and superior efficacy compared with ustekinumab regardless of patient demographics, disease characteristics or prior biologic exposure.